L Pusztai, T Karn, A Safonov, MM Abu-Khalaf… - Clinical Cancer …, 2016 - AACR
More than 70% of breast cancers contain lymphocytic infiltration in the stroma, and preclinical studies suggest that immunoediting and partial control of cancer progression by …
R Thomas, G Al-Khadairi, J Decock - Frontiers in oncology, 2021 - frontiersin.org
Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the …
The immune system is active in breast cancer, playing a dual role in tumor progression and in immune surveillance. Infiltrating immune cells are both prognostic and predictive of …
M Yi, D Jiao, S Qin, Q Chu, K Wu, A Li - Molecular cancer, 2019 - Springer
Immune checkpoint inhibitor (ICI) activates host's anti-tumor immune response by blocking negative regulatory immune signals. A series of clinical trials showed that ICI could …
C Solinas, A Gombos, S Latifyan, M Piccart-Gebhart… - ESMO open, 2017 - Elsevier
The immune tumour microenvironment has been shown to play a crucial role in the development and progression of cancer. Expression of gene signatures, reflecting immune …
P Ciciola, P Cascetta, C Bianco, L Formisano… - Journal of clinical …, 2020 - mdpi.com
Immunotherapy has recently emerged as a novel strategy for treating different types of solid tumors, with promising results. However, still a large fraction of patients do not primarily …
V Debien, A De Caluwé, X Wang… - NPJ Breast …, 2023 - nature.com
Recent progress in immunobiology has led the way to successful host immunity enhancement against breast cancer. In triple-negative breast cancer, the combination of …
Recently, the development of immunotherapy through the immune checkpoint blockade led to long-lasting responses in several types of cancers that are refractory to conventional …
Triple-negative breast cancer (TNBC) is heterogeneous cancer with poor prognosis among the other breast tumors. Rapid recurrence and increased progression rate could be reasons …